Drugs / allogeneic marrow stromal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05346120 | May 2022 → Dec 2023 | post-COVID-19 disorder | Sean Savitz | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic marrow stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05346120 ↗ |
| Known as | MSCs | “allogeneic marrow stromal cells (MSCs)” NCT05346120 ↗ |
| Route | Intravenous | “Single IV infusion of 6 million cells/kg allogeneic marrow stromal cells (MSCs) lasting approximately 30 minutes” NCT05346120 ↗ |